Under the partnership deal, the company will be responsible for distributing Pixyl’s software-as-a-Service (SaaS) solution, Neuro.MS.
The Neuro.MS SaaS solution has been designed for the diagnosis and treatment of MS patients.
It leverages advanced deep-learning technology to provide clinicians and radiologists with clinically relevant information regarding neurological disorders such as MS.
The solution automatically analyses MRI images of the brain to identify, quantify and track abnormalities within five minutes.
It offers access to quantified and classified white matter hyperintensities along with quantified measures of lesion volumes and brain atrophy.
Brainomix co-founder and CEO Dr Michalis Papadakis said: “We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions.
“We recognised that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions.
“We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”
The company will distribute Pixyl’s SaaS solution exclusively in Ireland, the US, the Nordics, and important markets across Eastern Europe.
A CE mark-approved Class IIA product, the Neuro.MS solution will be offered to the company’s existing customer base alongside its e-Stroke platform, a comprehensive stroke imaging solution.